explore -WSS

explore

author：entertainment 2025-10-01 05:38:25 - browse：76886

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： The EPA's new lead rule: How one expert crunched the numbers

hotspot

WSS

Juul spent big to court Black leaders to promote its e

What don’t we know about an Alzheimer’s drug side effect?

The EPA's new lead rule: How one expert crunched the numbers

SAMSHA loosens regulations on methadone treatment centers

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Time to name cancers by genetics, not organ of origin, expert says

Wikipedia

explore

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Do digital therapeutics have a future in medicine?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

UnitedHealth’s Optum accused of antitrust violations in California

Novavax promises a turnaround & Lilly roils the obesity market

Commercial surrogacy can be ethical, despite pope’s claims

After affirmative action ruling, medical educators look to 'holistic review'

Commercial surrogacy can be ethical, despite pope’s claims

Moonlake's readout produced a cash windfall. Risks remain

Will the market for weight loss drugs really reach $100 billion?

hotspot

Congressmen charge Covid hearing ‘could have been an email’

The EPA's new lead rule: How one expert crunched the numbers

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Pediatric cancer treatments threatened by a new FDA policy

Time to name cancers by genetics, not organ of origin, expert says

ReNAgade cuts staff seven months after raising $300 million

entertainment

hotspot

Wikipedia

explore